Fig. 6: Hepatic ARSA remodels lipid rafts in the liver. | Nature Communications

Fig. 6: Hepatic ARSA remodels lipid rafts in the liver.

From: Deep proteomic profiling unveils arylsulfatase A as a non-alcoholic steatohepatitis inducible hepatokine and regulator of glycemic control

Fig. 6: Hepatic ARSA remodels lipid rafts in the liver.

ARSA was overexpressed in the livers of male db/db mice using a liver-specific adeno-associated virus (ARSA-AAV, blue bars) and was compared with Control-AAV (white bars). a Sulfatide content in whole-liver extracts (n = 6/group), *P = 0.0130. b Lysophospholipid content (*P = 0.0209), c lysophospholipid classes (*P = 0.006 for LPC, *P = 0.0241 for LPS), and d lysophosphatidic acid in liver lipid rafts (n = 6/group, *P = 0.033). e Lysophospholipid classes in whole-liver extracts (n = 6/group). ARSA effect *P = 0.0122, *P = 0.002 for LPE. f Correlation of ARSA mRNA expression and lysophosphatidylcholine (LPC) content in human livers (n = 106). g Phospholipase A2 (PLA2) S505 phosphorylation in whole-liver and liver lipid rafts (n = 4/group, *P = 0.0001 for LR). Data are means ± SEM. *P < 0.05 vs. Control-AAV, as assessed by two-tailed unpaired t tests or linear regression analysis (f). LPA lysophosphatidic acid, LPC lysophosphatidylcholine, LPE lysophosphatidyl ethanolamine, LPG lysophosphatidyl glycerol, LPI lysophosphatidyl inositol, LPS lysophosphatidyl serine, PLA2 phospholipase A2. Source data are provided as a Source Data file.

Back to article page